Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture, Organoids and Organs-on-Chips 2021

Albert Folch's Biography



Albert Folch, Professor of Bioengineering, University of Washington

Albert Folch’s lab works at the interface between microfluidics and cancer. He received both his BSc (1989) and PhD (1994) in Physics from the University of Barcelona (UB), Spain, in 1989. During his Ph.D. he was a visiting scientist from 1990–91 at the Lawrence Berkeley Lab working on AFM under Dr. Miquel Salmeron. From 1994–1996, he was a postdoc at MIT developing MEMS under Martin Schmidt (EECS) and Mark Wrighton (Chemistry). In 1997, he joined Mehmet Toner’s lab as a postdoc at Harvard-MGH to apply soft lithography to tissue engineering. He has been at Seattle’s UW BioE since June 2000, where he is now a full Professor, accumulating over 9,800 citations. In 20 years, he has supervised 18 postdocs (17% of whom have reached faculty rank), 12 Ph.D. students (25% faculty rank), 15 M.S. students, and >40 undergraduates. In 2001 he received an NSF Career Award, in 2006 a NASA Space Act Award, and in 2014 he was elected to the AIMBE College of Fellows (Class of 2015). He serves on the Advisory Board of Lab on a Chip since 2006 and in the Editorial Board of Micromachines since 2019. He is the author of 5 books (sole author), including “Introduction to BioMEMS” (2012, Taylor&Francis), a textbook adopted by >88 departments in 18 countries, and “Microfluidics: Hidden in Plain Sight” (MIT Press, to appear in mid-2021). Since 2007, the lab runs a celebrated outreach art program called BAIT (Bringing Art Into Technology), which has produced seven exhibits, a popular resource gallery of >2,000 free images related to microfluidics and microfabrication, and a YouTube channel that plays microfluidic videos with music which accumulates ~157,000 visits since 2009.

Albert Folch Image

Tumor-on-a-Chip Platforms for Analyzing Intact Tumor Biopsies

Monday, 22 March 2021 at 13:30

Add to Calendar ▼2021-03-22 00:00:002021-03-22 01:00:00Europe/LondonTitle to be Confirmed.3D-Culture, Organoids and Organs-on-Chips 2021 in SELECTBIOenquiries@selectbiosciences.com

Cancer remains a major healthcare challenge worldwide. It is now well established that cancer cells constantly interact with fibroblast cells, endothelial cells, immune cells, signaling molecules, and the extracellular matrix in the tumor microenvironment (TME). Present tools to study drug responses and the TME have not kept up with drug testing needs. Oncology drugs typically take 10 years and cost an average of 1 billion dollars to develop. The number of clinical trials of combination therapies has been climbing at an unsustainable rate, with 3,362 trials launched since 2006 to test PD-1/PD-L1-targeted monoclonal antibodies alone or in combination with other agents. We have developed a microfluidic platform (called Oncoslice) for the delivery of multiple drugs with spatiotemporal control to live tumor biopsies, which retain the TME. We have developed the use of Oncoslice for the delivery of small-molecule cancer drug panels to glioblastoma (GBM) xenograft slices as well as to slices from patient tumors (GBM and colorectal liver metastasis). In addition, we have developed a precision slicing methodology that allows for producing large numbers of cuboidal micro-tissues (“cuboids”) from a single tumor biopsy. We have been able to trap cuboids in arrays of microfluidic traps in a multi-well platform. This work will potentially allow for the high-throughput application of drugs to intact human tumor tissues.


Add to Calendar ▼2021-03-22 00:00:002021-03-23 00:00:00Europe/London3D-Culture, Organoids and Organs-on-Chips 20213D-Culture, Organoids and Organs-on-Chips 2021 in SELECTBIOenquiries@selectbiosciences.com